Novartis Co-Develops Palazestrant as Roche’s SERD Misses Phase 3 Endpoint
Novartis is co-developing Palazestrant, an oral CERAN/SERD, with Olema and Pfizer in multiple breast cancer trials. Roche’s giredestrant failed to improve progression-free survival in phase 3, pressuring sector momentum and highlighting Palazestrant’s potential as an alternative if its trials succeed.
1. Roche’s Phase 3 SERD Trial Fails Primary Endpoint
Roche’s phase 3 PERSEVera study of giredestrant combined with palbociclib failed to achieve its primary objective of statistically significant progression-free survival improvement versus letrozole plus palbociclib, showing only a numerical benefit and triggering bearish sentiment across oestrogen receptor degrader stocks.
2. Novartis Advances Palazestrant in Breast Cancer Trials
Novartis is co-developing Palazestrant, a complete estrogen receptor antagonist and oral selective degrader, with Olema Pharmaceuticals and Pfizer, with multiple ongoing clinical trials in advanced and early-stage breast cancer and plans to monitor next readouts as potential catalysts for its oncology portfolio.